CIK 0001799850
RCOR Renovacor, Inc.
Insider trading from SEC Form 4. Last filing Dec 5, 2022.
In brief
Renovacor, Inc. (RCOR) has 11 SEC Form 4 filings on file from 11 insiders, the latest filed on Dec 5, 2022. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at Renovacor, Inc., scored.
Transactions
Every row filed, 43 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 1, 2022 | Joan Lau director | DDisposition to issuer Stock Optionderivative | -24,000 | $0.00 | $0 | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Wendy F Dicicco Chief Financial Officer | DDisposition to issuer Common Stock | -18,800 | - | - | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Jonas Grossman director | DDisposition to issuer Common Stock | -394,657 | - | - | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Magdalene Cook Chief Executive Officer | DDisposition to issuer Common Stock | -451,448 | - | - | 70,825 | Dec 5, 2022 |
| Dec 1, 2022 | Matthew Killeen Chief Scientific Officer | DDisposition to issuer Common Stock | -5,275 | - | - | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Joseph S Carroll Chief Accounting Officer | DDisposition to issuer Common Stock | -8,195 | - | - | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Gregory F Covino director | DDisposition to issuer Stock Optionderivative | -24,000 | $0.00 | $0 | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Thomas E. Needham Jr. director | DDisposition to issuer Stock Optionderivative | -24,000 | $0.00 | $0 | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Marc Semigran Chief Medical Officer | DDisposition to issuer Common Stock | -17,425 | - | - | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Edward J. Benz JR director | AGrant or award Common Stock | +3,586 | - | - | 3,586 | Dec 5, 2022 |
| Dec 1, 2022 | Gbolahan Amusa director | DDisposition to issuer Common Stock | -278,588 | - | - | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Joan Lau director | DDisposition to issuer Stock Optionderivative | -12,000 | $0.00 | $0 | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Gbolahan Amusa director | DDisposition to issuer Stock Optionderivative | -24,000 | $0.00 | $0 | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Thomas E. Needham Jr. director | DDisposition to issuer Stock Optionderivative | -12,000 | $0.00 | $0 | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Matthew Killeen Chief Scientific Officer | DDisposition to issuer Stock Optionderivative | -194,049 | $0.00 | $0 | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Jonas Grossman director | DDisposition to issuer Stock Optionderivative | -24,000 | $0.00 | $0 | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Marc Semigran Chief Medical Officer | AGrant or award Common Stock | +35,226 | - | - | 35,226 | Dec 5, 2022 |
| Dec 1, 2022 | Wendy F Dicicco Chief Financial Officer | AGrant or award Common Stock | +4,329 | - | - | 4,329 | Dec 5, 2022 |
| Dec 1, 2022 | Edward J. Benz JR director | DDisposition to issuer Common Stock | -3,586 | - | - | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Gregory F Covino director | DDisposition to issuer Stock Optionderivative | -12,000 | $0.00 | $0 | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Joseph S Carroll Chief Accounting Officer | DDisposition to issuer Stock Optionderivative | -25,884 | $0.00 | $0 | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Magdalene Cook Chief Executive Officer | DDisposition to issuer Common Stock | -70,825 | - | - | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Jonas Grossman director | DDisposition to issuer Stock Optionderivative | -12,000 | $0.00 | $0 | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Marc Semigran Chief Medical Officer | DDisposition to issuer Common Stock | -35,226 | - | - | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Gbolahan Amusa director | DDisposition to issuer Stock Optionderivative | -12,000 | $0.00 | $0 | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Edward J. Benz JR director | DDisposition to issuer Stock Optionderivative | -9,060 | $0.00 | $0 | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Matthew Killeen Chief Scientific Officer | DDisposition to issuer Stock Optionderivative | -10,550 | $0.00 | $0 | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Joseph S Carroll Chief Accounting Officer | DDisposition to issuer Stock Optionderivative | -16,350 | $0.00 | $0 | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Wendy F Dicicco Chief Financial Officer | DDisposition to issuer Common Stock | -4,329 | - | - | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Magdalene Cook Chief Executive Officer | AGrant or award Common Stock | +147,083 | - | - | 147,083 | Dec 5, 2022 |
| Dec 1, 2022 | Joseph S Carroll Chief Accounting Officer | DDisposition to issuer Stock Optionderivative | -29,000 | $0.00 | $0 | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Marc Semigran Chief Medical Officer | DDisposition to issuer Stock Optionderivative | -88,991 | $0.00 | $0 | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Wendy F Dicicco Chief Financial Officer | DDisposition to issuer Stock Optionderivative | -10,936 | $0.00 | $0 | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Edward J. Benz JR director | DDisposition to issuer Stock Optionderivative | -24,000 | $0.00 | $0 | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Magdalene Cook Chief Executive Officer | DDisposition to issuer Common Stock | -147,083 | - | - | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Marc Semigran Chief Medical Officer | DDisposition to issuer Stock Optionderivative | -169,849 | $0.00 | $0 | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Wendy F Dicicco Chief Financial Officer | DDisposition to issuer Stock Optionderivative | -14,553 | $0.00 | $0 | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Edward J. Benz JR director | DDisposition to issuer Stock Optionderivative | -12,000 | $0.00 | $0 | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Magdalene Cook Chief Executive Officer | DDisposition to issuer Stock Optionderivative | -238,793 | $0.00 | $0 | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Marc Semigran Chief Medical Officer | DDisposition to issuer Stock Optionderivative | -34,850 | $0.00 | $0 | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Wendy F Dicicco Chief Financial Officer | DDisposition to issuer Stock Optionderivative | -37,575 | $0.00 | $0 | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Magdalene Cook Chief Executive Officer | DDisposition to issuer Stock Optionderivative | -141,625 | $0.00 | $0 | 0 | Dec 5, 2022 |
| Dec 1, 2022 | Wendy F Dicicco Chief Financial Officer | DDisposition to issuer Stock Optionderivative | -155,325 | $0.00 | $0 | 0 | Dec 5, 2022 |
Insiders
Everyone who has filed a Form 4 here.
- Gbolahan Amusadirector
- Edward J. Benz JRdirector
- Gregory F Covinodirector
- Joseph S CarrollChief Accounting Officer
- Magdalene CookChief Executive Officer
- Wendy F DiciccoChief Financial Officer
- Jonas Grossmandirector, owner, other
- Matthew KilleenChief Scientific Officer
- Joan Laudirector
- Thomas E. Needham Jr.director
- Marc SemigranChief Medical Officer
Questions about RCOR
Answered from the filings on this page, as of the latest one.
Are insiders buying RCOR?
No. In the last 90 days no insider at Renovacor, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade RCOR on the open market?
No open-market trade has been scored at Renovacor, Inc.. The latest Form 4 on file was filed on Dec 5, 2022 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at Renovacor, Inc.?
11 people have filed a Form 4 at Renovacor, Inc., among them Gbolahan Amusa (director), Edward J. Benz JR (director), Gregory F Covino (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.